Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Broadwood Capital Trims Its Stake in Questcor Pharmaceuticals Inc (QCOR)

Neal C. Bradsher‘s Broadwood Capital has trimmed its stake in Questcor Pharmaceuticals Inc (NASDAQ:QCOR) by selling 20,000 shares. According to the filing with the SEC, Broadwood disposed the securities in one deal at a price of $65 per share. Following the transaction, the fund still owns around 2.78 million shares. The stake currently amasses around 4.5% of the company’s stock.

Questcor Pharmaceuticals Inc (NASDAQ:QCOR)

Overall, Broadwood Capital reduced significantly its position in biopharmaceutical company Questcor Pharmaceuticals Inc (NASDAQ:QCOR). In its latest 13F, the fund revealed holding almost 3.3 million shares of the company. Palo Alto Investors, led by William Leland Edwards, is another investor with a $38.05 million stake, which contains around 656,000 shares of the company. Christopher R. Hansen’s Valiant Capital disclosed holding 531,600 shares in its latest 13F.

Questcor Pharmaceuticals Inc (NASDAQ:QCOR)’s stock returned almost 30% over the past six months, trailing a P/E of 14.8x. A couple of days ago, the company paid a quarterly dividend of $0.30 per share. Last month, Questcor Pharmaceuticals Inc (NASDAQ:QCOR) announced that it has repurchased around 500,000 shares of its common stock at an average price of $57.21 apiece.

Broadwood Capital is a mid-sized New York City-based fund with an equity portfolio worth around $468.5 million. At the beginning of the month, the fund disclosed raising its stake in BioTime, Inc. (NYSEMKT:BTX) to 9.52 million shares, from some 9.02 million held previosly. Overall, the stake currently amasses 14.1% of BioTime’s outstanding stock.

Among the largest stakes revealed by Broadwood in its latest 13F, is STAAR Surgical Company (NASDAQ:STAA), in which the fund holds a $86.68 million stake, which amasses 6.4 million shares. Another one is Monster Beverage Corp (NASDAQ:MNST), in which Broadwood owns 1.61 million shares, worth $84.08 million.

Disclosure: none

Recommended Reading:

Hedge Fund News: Rob Citrone, David Tepper & Paul Singer

Hedge Fund Highlights: Steven Cohen, Barry Rosenstein & George Soros

Corvex Capital Is Going Long Signet Jewelers Ltd. (SIG)

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!